Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
LaFleur Minerals Commences Diamond Drilling at the Swanson Gold Deposit and Completes Independent Valuation of the Beacon Gold Mill
